Early corticosteroid avoidance in kidney transplant recipients receiving ATG-F induction: 5-year actual results of a prospective and randomized study

American Journal of Transplantation

Volumn 14, Issue 11, 2014, Pages 2556-2564

  Cantarovich, D ^a   Rostaing, L ^b   Kamar, N ^b   Ducloux, D ^c   Saint Hillier, Y ^c   Mourad, G ^d   Garrigue, V ^d   Wolf, P ^e   Ellero, B ^e   Cassuto, E ^f   Albano, L ^f   Volp A ^g   Soulillou, J P ^a  

^a NANTES UNIVERSITY HOSPITAL   (France)

^b Dialyse et Transplantation d'Organeshôpital Rangueil   (France)

^c HÔPITAL SAINT JACQUES   (France)

^d LAPEYRONIE HOSPITAL   (France)

^e HÔPITAL DE HAUTEPIERRE   (France)

^f PASTEUR HOSPITAL   (France)

^g Frankfurt Am Main   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; CYCLOSPORIN A; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; THYMOCYTE ANTIBODY;

ACUTE GRAFT REJECTION; ADOLESCENT; ADULT; AGED; ARTICLE; CONTROLLED STUDY; CORTICOSTEROID THERAPY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DIABETES MELLITUS; DRUG EFFICACY; DRUG SAFETY; DYSLIPIDEMIA; FEASIBILITY STUDY; FEMALE; FOLLOW UP; GRAFT FAILURE; GRAFT RECIPIENT; GRAFT SURVIVAL; HUMAN; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FUNCTION; KIDNEY GRAFT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEOPLASM; POSTTRANSPLANT LYMPHOPROLIFERATIVE DISEASE; RANDOMIZED CONTROLLED TRIAL; SURVIVAL TIME; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; CLINICAL TRIAL; MIDDLE AGED; PHASE 4 CLINICAL TRIAL; PROSPECTIVE STUDY; SURVIVAL RATE; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; FEMALE; GRAFT SURVIVAL; HUMANS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SURVIVAL RATE; TRANSPLANTATION CONDITIONING; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84911457154     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/ajt.12866     Document Type: Article

References (39)

1. Calne RY., Renal transplantaion in man: A review. Br J Surg 1964; 51: 282-293.
2. Benfield MR, Bartosh S, Ikle D, et al. A randomized double-blind, placebo controlled trial of steroid withdrawal after pediatric renal transplantation. Am J Transplant 2010; 10: 81-88.
3. Nehus E, Goebel J, Abraham E., Outcomes of steroid-avoidance protocols in pediatric kidney transplant recipients. Am J Transplant 2012; 12: 3441-3448.
4. Cantarovich D, Giral-Classe M, Hourmant M, et al. Prevention of acute rejection with antithymocyte globulin, avoiding corticosteroids, and delaying cyclosporin after renal transplantation. Nephrol Dial Transplant 2000; 15: 1673-1676.
5. Cantarovich D, Giral-Classe M, Hourmant M, et al. Low incidence of kidney rejection after simultaneous kidney-pancreas transplantation after antithymocyte globulin induction and in the absence of corticosteroids: Results of a prospective pilot study in 28 consecutive cases. Transplantation 2000; 69: 1505-1508.
6. Krämer BK, Klinger M, Vítko Š, et al. Tacrolimus-based, steroid-free regimens in renal transplantation: 3-year follow-up of the ATLAS trial. Transplantation 2012; 94: 492-498.
7. Luan FL, Steffick DE, Ojo AO., Steroid-free maintenance immunosuppression in kidney transplantation: Is it time to consider it as a standard therapy ? Kidney Int 2009; 76: 825-830.
8. Knight SR, Morris PJ., Steroid avoidance or withdrawal after renal transplantation increases the risk of acute rejection but decreases cardiovascular risk. A meta-analysis. Transplantation 2010; 89: 1-14.
9. Naesens M, Salvatierra O, Benfield M, et al. Subclinical inflammation and chronic renal allograft injury in a randomized trial on steroid avoidance in pediatric kidney transplantation. Am J Transplant 2012; 12: 2730-2743.
10. Morgan RD, O'Callaghan JM, Knight SR, Morris PJ., Alemtuzumab induction therapy in kidney transplantation: A systematic review and meta-analysis. Transplantation 2012; 93: 1179-1188.
11. Cai J, Terasaki PI., Induction immunosuppression improves long-term graft and patient outcome in organ transplantation: An analysis of United Network for Organ Sharing registry data. Transplantation 2010; 90: 1511-1515.
12. Brennan DC, Daller JA, Lake KD, Cibrik D, Del Castillo D., Rabbit antithymocyte globulin versus basiliximab in renal transplantation. N Engl J Med 2006; 355: 1967-1977.
13. Bamoulid J, Courivaud C, Coaquette A, et al. Subclinical Epstein-Barr virus viremia among adult renal transplant recipients: Incidence and consequences. Am J Transplant 2013; 13: 656-662.
14. Opelz G, Naujokat C, Daniel V, Terness P, Döhler B., Disassociation between risk of graft loss and risk of non-Hodgkin lymphoma with induction agents in renal transplant recipients. Transplantation 2006; 81: 1227-1233.
15. Dharnidharka VR, Stevens G., Risk for post-transplant lymphoproliferative disorder after polyclonal antibody induction in kidney transplantation. Pediatr Transplant 2005; 9: 622-626.
16. Caillard S, Dharnidharka V, Agodoa L, Bohen E, Abbott K., Posttransplant lymphoproliferative disorders after renal transplantation in the United States in era of modern immunosuppression. Transplantation 2005; 80: 1233-1243.
17. Cantarovich D, Rostaing L, Kamar N, et al. Corticosteroid avoidance in adult kidney transplant recipients under rabbit anti-T-lymphocyte globulin, mycophenolate mofetil and delayed cyclosporine microemulsion introduction. Transpl Int 2010; 23: 313-324.
18. Matas AJ., Chronic progressive calcineurin nephrotoxicity: An overstated concept. Am J Transplant 2011; 11: 687-692.
19. Bemelman FJ, de Maar EF, Press RR, et al. Minimization of maintenance immunosuppression early after renal transplantation: An interim analysis. Transplantation 2009; 88: 421-428.
20. Lightner A, Concepcion W, Grimm P., Steroid avoidance in renal transplantation. Curr Opin Organ Transplant 2011; 16: 477-482.
21. Kukla A, Chen E, Spong R, et al. Recurrent glomerulonephritis under rapid discontinuation of steroids. Transplantation 2011; 91: 1386-1391.
22. Opelz G, Döhler B., Association between steroid dosage and death with a functioning graft after kidney transplantation. Am J Transplant 2013; 13: 2096-2105.
23. Woodle ES, First MR, Pirsch J, Shihab F, Gaber AO, Van Veldhuisen PA., A prospective, randomized, double-blind, placebo-controlled multicenter trial comparing early (7 day) corticosteroid cessation versus long-term, low-dose corticosteroid therapy. Ann Surg 2008; 248: 564-577.
24. De Jong EC, Vieira PL, Kalinski P, Kapsenberg ML., Corticosteroids inhibit the production of inflammatory mediators in immature monocyte-derived DC and induce the development of tolerogenic DC3. J Leukoc Biol 1999; 66: 201-204.
25. Cancedda C, Filaci G, Puppo F, Ghio M, Contini P, Indiveri F., Immune homeostasis requires several biologic factors including glucocorticoid hormones. Ann N Y Acad Sci 2002; 966: 49-63.
26. De Bosscher K, Haegeman G, Elewaut D., Targeting inflammation using selective glucocorticoid receptor modulators. Curr Opin Pharmacol 2010; 10: 497-504.
27. Almawi WY, Melemedjian OK., Negative regulation of nuclear factor-kappaB activation and function by glucocorticoids. J Mol Endocrinol 2002; 28: 69-78.
28. Merion RM, Howell T, Bromberg JS., Partial T-cell activation and anergy induction by polyclonal antithymocyte globulin. Transplantation 1998; 65: 1481-1489.
29. Genestier L, Fournel S, Flacher M, Assossou O, Revillard JP, Bonnefoy-Berard N., Induction of Fas (Apo-1, CD95)-mediated apoptosis of activated lymphocytes by polyclonal antithymocyte globulins. Blood 1998; 91: 2360-2368.
30. Matas AJ., Steroid elimination-who, when, how ? Transplant Proc 2008; 40: S52-S56.
31. Thaunat O, Morelon E., [Cancer and immunosuppression: Pro- and antitumoral effects of immunosuppressive drugs]. Nephrol Ther 2005; 1: 23-30.
32. Tiede C, Maecker-Kolhoff B, Klein C, Kreipe H, Hussein K., Risk factors and prognosis in T-cell posttransplantation lymphoproliferative diseases: Reevaluation of 163 cases. Transplantation 2013; 95: 479-488.
33. Bichari W, Bartiromo M, Mohey H, et al. Significant risk factors for occurrence of cancer after renal transplantation: A single center cohort study of 1265 cases. Transplant Proc 2009; 41: 672-673.
34. Wisgerhof HC, Edelbroek JRJ, de Fijter JW, et al. Subsequent squamous- and basal-cell carcinomas in kidney-transplant recipients after the first skin cancer: Cumulative incidence and risk factors. Transplantation 2010; 89: 1231-1238.
35. Preciado DA, Matas A, Adams GL., Squamous cell carcinoma of the head and neck in solid organ transplant recipients. Head Neck 2002; 24: 319-325.
36. Baibergenova AT, Weinstock MA., Oral prednisone use and risk of keratinocyte carcinoma in non-transplant population. The VATTC trial. J Eur Acad Dermatol Venereol 2012; 26: 1109-1115.
37. Dantal J, Hourmant M, Cantarovich D, et al. Effect of long-term immunosuppression in kidney-graft recipients on cancer incidence: Randomised comparison of two cyclosporin regimens. Lancet 1998; 351: 623-628.
38. Otley CC, Maragh SLH., Reduction of immunosuppression for transplant-associated skin cancer: Rationale and evidence of efficacy. Dermatol Surg 2005; 31: 163-168.
39. Scandling JD, Busque S, Dejbakhsh-Jones S, et al. Tolerance and withdrawal of immunosuppressive drugs in patients given kidney and hematopoietic cell transplants. Am J Transplant 2012; 12: 1133-1145.